header image

[Sign Up Now] to Receive Our FREE Daily SCVTV-SCVNews Digest by E-Mail

Santa Clarita CA
Today in
S.C.V. History
January 30
2003 - Actress & big cat rescuer Tippi Hedren of Acton inducted into Hollywood Walk of Fame [story]
Tippi Hedren

SILVER SPRING, Md. — Scott Gottlieb, the commissioner of the U.S. Food and Drug Administration, addressed the issue of drug shortages in the following statement released Thursday:

Without question, one of the most frustrating challenges that health care providers and patients must contend with is when a drug that’s medically necessary and critical to patient care is unavailable due to a shortage.

We know that the uncertainty over how long a drug will be in shortage, how to ration supplies in the meantime, or worse, how to prepare for a sudden event that might place unforeseen demands on a product that’s in short supply, adds burdens and stress on providers and patients.

The FDA also understands that hospitals and other healthcare facilities can feel blindsided by these shortages. They can seem abrupt and may be. Drug shortages also have significant costs to our overall health care system. The FDA is committed to taking new steps to address the root cause of more of these shortage situations.

While the causes of drug shortages vary, most shortages are due to disruptions in supply chain availability of actively marketed products. Among these interruptions, manufacturing and quality issues are the leading causes of drug shortages.

This includes outdated equipment in need of repair or replacement, unexpected issues with a product’s composition, and a manufacturer’s inability to maintain facility and product quality. The availability of raw materials can also be a key factor in creating supply disruptions.

A disruption from one supplier of raw materials can affect production for many drug makers who all depend on that one source of raw material. Companies that supply raw materials can also be subject to quality problems, leading to shortages.

Only two percent of shortages are a result of product discontinuation. For example, when companies that make competing products merge, and discontinue one of the competing products, this can cause a shortage. Manufacturers often make production decisions based on business considerations, such as a product’s profitability, manufacturing costs, distribution quotas and patent life.

We know that business decisions at any point along the drug supply chain can lead to shortages.

Historically, many drugs in short supply have been low-profit generic medications, for which the investment needed to ensure continued production can be less than that for higher profit products.

Even in the absence of any production issues and decisions, there are other issues that can precipitate a shortage.

For example, an unforeseen increase in clinical demand, changes in clinical practice guidelines, or even FDA approval of a new indication for an existing drug, can all lead to an unexpected surge in demand for a particular medicine. The increased demand can, in turn, lead to a shortage of that specific drug.

Given these challenges, the FDA is focused on doing all we can to mitigate existing shortages and prevent them from occurring. While we help avert and minimize shortages in many ways, the FDA can have the best impact by working more closely with sponsors to help prevent shortages before they occur.

This starts with the FDA knowing about potential supply disruption well in advance of an actual shortage.

The Food and Drug Administration Safety and Innovation Act of 2012 (known as FDASIA) generally requires manufacturers to notify us of any disruptions, such as manufacturing changes, production or shipping delays, and product discontinuations likely to affect their supply of prescription drugs for serious illnesses. This vital information allows the FDA to execute other actions within our authority to help avert impending shortages or lessen their impact.

These notification requirements are critical, but there are many times manufacturers abruptly discontinue, limit, or delay production under circumstances outside those for which they are specifically required to provide advance notice to the agency.

There are other times when companies notify the FDA of potential supply disruptions, but don’t provide enough details to allow us to make the fullest use of our resources to address the shortage. We need to know as much as possible about these shortages.

While this information sharing can sometimes be challenging, the more information manufacturers can supply the FDA, the more we can do to help mitigate the shortage. To address these challenges and opportunities, the FDA is exploring additional ways that we can encourage companies to voluntarily share more timely information about potential supply disruptions.

We may be able to take new steps to clarify the information the agency requires to inform us better about the extent of a shortage problem. We’re also looking at what additional steps we can take, under the existing law, to make the communications we receive more actionable.

This includes additional information that can help the FDA develop more effective options for managing a shortage.

Our ability to help resolve shortages also relies on industry seeking approval for drugs currently in short supply. When that opportunity arises, we do what we can to prioritize these circumstances. For example, if a new production facility or supplier is needed, we have the regulatory authority to expedite facility inspections and drug application assessments so that the facility can become operational as soon as possible.

We can also expedite review of a new or generic drug application that, if approved, may serve as an alternative therapy to a product facing a shortage. Even when a shortage situation is urgent, patient safety remains our top priority. We make sure that any approvals of such alternate therapies meet our standards.

Although we cannot mandate submission of applications for products in short supply, the FDA does alert other manufacturers of similar or alternative products to consider ramping up production to meet an anticipated increased demand for their product.
In cases where alternative manufacturing is not available in the U.S., or the manufacturers of U.S.-marketed products are not able to expand production, we may explore importation of a product from a foreign manufacturing source until the shortage is resolved. We carefully evaluate the overseas manufacturing site and product to protect U.S. patients.

We’re also taking steps to bring on new technology that can improve manufacturing, to help reduce the chance that supply disruptions will occur. The FDA has implemented an emerging technology program and established an emerging technology team to engage with companies about new production technologies that could, in the long run, prevent drug shortages caused by product quality and manufacturing problems.

One such technology is continuous manufacturing. As with any new technology, implementing CM presents challenges, such as the initial cost of investing in new equipment. The FDA is taking steps to reduce the cost and uncertainty of adopting CM as an important, long-term solution to improve manufacturing reliability. The goal is to prevent and mitigate future drug shortages.

Finally, as we learned from our experience in responding to the devastation in Puerto Rico following Hurricane Maria last year, predicting some forces that can lead to shortages is very hard. Given the complexities involved in drug manufacturing, especially for sterile injectable drugs, problems can arise at any point in the process.

When companies are proactive and have backup lines, and facilities and raw material suppliers are prepared for when things go wrong, we can more readily prevent future shortages.

Shortages are an inevitable consequence of an imperfect system. With better planning, we can minimize shortages throughout the supply chain. But, in the near term, we won’t be able to fully eliminate the possibility that new shortages will arise.

Meaningfully impacting the structures and market challenges that can give rise to shortages will require more coordination among public and private stakeholders.

We’re evaluating our current authorities to see what more we can do to better mitigate and prevent shortages, including receiving additional, key information from industry when they notify the agency about a possible shortage and identifying all establishments where manufacturing is performed associated with listed drugs and the type of operation performed at each such establishment.

It’s essential that we evaluate what additional steps we can take to reduce the incidence and impact of shortages.

It may also require us to work with Congress to re-evaluate our current authorities in these areas. One consideration might be to expand the FDA’s existing authority to require applicants of certain drugs to conduct a risk assessment to identify the vulnerabilities in their drug supply, including vulnerabilities that could cause a shortage, and establish risk mitigation plans to address those risks.

Anticipation, foresight and communication are keys to preventing and reducing the impact of shortages. When a manufacturer provides the FDA with advance notification before production is halted or put on hold, and a contingency plan is put in place, shortages can be more easily mitigated.

Without such efforts, shortages will certainly occur at a higher rate and their impacts will be greater than necessary.

To achieve our public health goals, the FDA needs to work collaboratively with industry. The agency cannot require a company to produce a drug, even if it is medically necessary. The agency cannot require a manufacturer to increase production of a drug, and we cannot control how much of the drug is distributed or which purchasers will be given priority.

And the FDA has no authority over business decisions that affect the supply of a drug made by manufacturers or other entities in the supply chain.

We must all work together to ensure that the supply chain infrastructure can withstand inevitable and unexpected disruptions. Mitigating drug shortages requires a sustained effort by industry, the FDA, and other partners to return to production levels that adequately meet the needs of patients.

We’re pursuing new ways to support industry efforts to identify critical facilities and products and develop such plans.

We’ll continue to do all we can to address these shortages. I’ll have more to share in the coming months.

Comment On This Story
COMMENT POLICY: We welcome comments from individuals and businesses. All comments are moderated. Comments are subject to rejection if they are vulgar, combative, or in poor taste.
REAL NAMES ONLY: All posters must use their real individual or business name. This applies equally to Twitter account holders who use a nickname.


You can be the first one to leave a comment.

Leave a Comment

Latest Additions to SCVNews.com
Three Santa Clarita music educators were recognized Saturday, Jan. 21, for their contributions to music education at the 2023 Southern California School Band & Orchestra Association Winter Conference.
School Band Association Recognizes Hart District Music Teachers
A workshop about “Basics of Filing Taxes and Family Law Issues,” hosted by Zonta Club of Santa Clarita Valley, will help participants “learn about filing taxes – whether you file your own or not” and “Family Law issues - divorce, child custody, and support.”
Feb. 18: Zonta’s Upcoming Workshop to Highlight Filing Taxes, Family Law Issues
Mission Valley Bancorp announced Monday a net income of $4.8 million, or $1.45 per diluted share, for the year ended Dec. 31, 2022, compared to net income of $5.0 million, or $1.50 per diluted share, for the year ended Dec. 31, 2021.
Mission Valley Bank Announces Record Loan Growth, Cash Dividend
The city of Santa Clarita’s Film Office released the nine productions currently filming in the Santa Clarita Valley for the week of Monday, Jan. 30 – Sunday, Feb. 5.
‘NCIS,’ ‘CSI: Vegas’ Among Nine Productions Currently Filming in SCV
California State University, Northridge film students, along with faculty and alumni have produced a public service announcement to address the ongoing fentanyl crisis and educate the public about the dangers of fentanyl pills.
CSUN, Law Enforcement Partner to Produce Fentanyl PSA
In 2019, Valencia High School student, Pedro Roman, was diagnosed with Acute Lymphoblastic Leukemia.
Feb. 4: Pedro Roman Memorial Blood Drive
Registration is now open for Family Promise of Santa Clarita Valley’s second poker night fundraiser, “All In for Family Promise.” The event will take place on Friday, March 3, at the Canyon Country Community Center.
March 3: Family Promise Hosting Poker Tourney, Sip & Paint Fundraiser
The regular meeting of the William S. Hart Union High School District’s Governing Board will take place Wednesday, Feb. 1, beginning with closed session at 6 p.m., followed immediately by open session at 7 p.m.
Feb. 1: Hart Board Scheduled to Discuss Proposed Teacher Pay Increase
Sulphur Springs Union School District will host the annual Many Families, One Community Event on Saturday, Feb. 25.
Sulphur Springs, Hart Districts Hosting Many Families One Community Event
Los Angeles County Department of Economic Opportunity has joined business and community leaders to launch the Fair Chance Hiring Program, galvanizing the county’s business community to adopt Fair Chance hiring practices with the goal of getting 200 local businesses to commit to hiring system-impacted individuals this year.
L.A. County Launches Fair Chance Hiring Program
The regular board meeting of the Saugus Union School District Governing Board will be held Tuesday, Jan. 31, beginning with a closed session at 5:30 p.m., followed immediately by open session at 6:30 p.m.
Jan. 31: SUSD Board Slated to Discuss Future Enrollment Projections
The Santa Clarita Valley Men of Harmony Barbershop Chorus will return on Valentine's Day, Feb. 14, to deliver singing valentines after being unavailable during the COVID-19 pandemic.
Feb. 14: Local Barbershop Quartet to Deliver Singing Valentines
The Los Angeles County Health Officer is issuing a Cold Weather Alert for the Santa Clarita Valley Tuesday through Thursday due to the National Weather Service’s forecast for low temperatures.
Cold Weather Alert Issued for SCV
Because of the recent rainfall, Los Angeles County Health Officer, Muntu Davis, MD, MPH, is cautioning residents that bacteria, chemicals, debris, trash, and other public health hazards from city streets and mountain areas are likely to contaminate ocean waters at and around discharging storm drains, creeks and rivers after a rainfall.
Recent Rainfall Prompts Ocean Water Advisory for All L.A. County Beaches
The California Transportation Commission allocated over $988 million Friday to repair and improve transportation infrastructure throughout the state.
California Invests Nearly $1 Billion for Transportation Improvements
2003 - Actress & big cat rescuer Tippi Hedren of Acton inducted into Hollywood Walk of Fame [story]
Tippi Hedren
Three new educational videos greet visitors to the Placerita Nature Center to help them understand what they're seeing along the trails.
Educational Videos Unveiled at Placerita Nature Center
1945 - Local residents vote 1,184 to 7 (correct, seven) to create SCV high school district [story]

1850 - Death Valley '49er William Robinson dies in Soledad Canyon from drinking too much cool water [story]
Leaving Death Valley
The Los Angeles County Department of Public Health confirmed 19 new deaths throughout L.A. County, 1,123 new cases countywide and 29 new cases in the Santa Clarita Valley.
Friday COVID Roundup: L.A. County Remains in Low Community Level
Teams from the city of Santa Clarita, Santa Clarita Valley Sheriff's Station, Los Angeles County Fire Department and loanDepot competed on Wednesday, Jan. 25 in the Magic Mountain Sky Tower Challenge.
L.A. County Fire Wins Magic Mountain Sky Tower Challenge
Friends of the Children – Los Angeles presented Los Angeles County Supervisor Kathryn Barger with the "Power of One" award at their inaugural Women's Leadership Breakfast held Friday, Jan. 27 at The California Club. Barger was selected to receive the award for her work and dedication to supporting and safeguarding children in Los Angeles County, especially those within the foster care system.
Barger Tapped by Friends of the Children L.A. for ‘Power of One’ Award
The Santa Clarita Artists Association has announced its new Board of Directors for 2023.
Santa Clarita Artists Association Announces 2023 Board
The North County I-5 Enhancements Project has announced that Santa Clarita Valley residents should prepare for a variety of lane reductions and road closures for the week of Jan. 27-Feb. 3.
Jan. 27-Feb. 3: Portions of The Old Road Closed for I-5 Enhancements Project
%d bloggers like this: